SL
SVB Leerink Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
201
Bruker
BRKR
$4.67B
|
PS
Puneet Souda
| $30.77 | $87 |
183%
upside
| Outperform |
5 May ‘22
3 years ago |
|
202
Protagonist Therapeutics
PTGX
$3.46B
|
JS
Joseph Schwartz
| $55.60 | $30 |
46%
downside
| Outperform |
5 May ‘22
3 years ago |
|
203
Axogen
AXGN
$741M
|
DA
Danielle Antalffy
| $16.10 | $14 |
13%
downside
| Outperform |
5 May ‘22
3 years ago |
|
204
Tandem Diabetes Care
TNDM
$841M
|
DA
Danielle Antalffy
| $12.45 | $110 |
784%
upside
| Market Perform |
5 May ‘22
3 years ago |
|
205
Compass Therapeutics
CMPX
$599M
|
AB
Andrew Berens
| $3.49 | $11 |
215%
upside
| Outperform |
5 May ‘22
3 years ago |
|
206
Zimmer Biomet
ZBH
$20.7B
|
DA
Danielle Antalffy
| $104.44 | $140 |
34%
upside
| Outperform |
4 May ‘22
3 years ago |
|
207
AtriCure
ATRC
$1.78B
|
DA
Danielle Antalffy
| $35.89 | $75 |
109%
upside
| Outperform |
4 May ‘22
3 years ago |
|
208
uniQure
QURE
$957M
|
JS
Joseph Schwartz
| $17.45 | $56 |
221%
upside
| Outperform |
3 May ‘22
3 years ago |
|
209
Lantheus
LNTH
$3.63B
|
DA
Danielle Antalffy
| $53.34 | $100 |
87%
upside
| Outperform |
2 May ‘22
3 years ago |
|
210
DexCom
DXCM
$30.5B
|
DA
Danielle Antalffy
| $77.78 | $125 |
61%
upside
| Outperform |
29 Apr ‘22
3 years ago |
|
211
Alkermes
ALKS
$4.66B
|
MG
Marc Goodman
| $28.25 | $27 |
4%
downside
| Market Perform |
28 Apr ‘22
3 years ago |
|
212
Boston Scientific
BSX
$160B
|
DA
Danielle Antalffy
| $107.89 | $48 |
56%
downside
| Market Perform |
28 Apr ‘22
3 years ago |
|
213
Viking Therapeutics
VKTX
$2.87B
|
TS
Thomas Smith
| $25.56 | $12 |
53%
downside
| Outperform |
28 Apr ‘22
3 years ago |
|
214
Edwards Lifesciences
EW
$46.9B
|
DA
Danielle Antalffy
| $79.86 | $138 |
73%
upside
| Outperform |
27 Apr ‘22
3 years ago |
|
215
Abbott
ABT
$230B
|
DA
Danielle Antalffy
| $131.94 | $140 |
6%
upside
| Market Perform |
21 Apr ‘22
3 years ago |
|
|
GNFT
216
Genfit
GNFT
$200M
|
TS
Thomas Smith
| $3.99 | $10 |
151%
upside
| Outperform |
11 Apr ‘22
3 years ago |
|
217
Enliven Therapeutics
ELVN
$1.2B
|
JS
Joseph Schwartz
| $20.24 | $4 |
80%
downside
| Market Perform |
6 Apr ‘22
3 years ago |
|
218
Alignment Healthcare
ALHC
$3.2B
|
WM
Whit Mayo
| $16.14 | $19 |
18%
upside
| Outperform |
4 Apr ‘22
3 years ago |
|
219
ARS Pharmaceuticals
SPRY
$1.06B
|
DG
Daina Graybosch
| $10.76 | $1.80 |
83%
downside
| Market Perform |
1 Apr ‘22
3 years ago |
|
|
OKUR
220
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$35.2M
|
JS
Joseph Schwartz
| $2.60 | $150 |
5,669%
upside
| Outperform |
24 Mar ‘22
3 years ago |
|
221
Synlogic
SYBX
$17.1M
|
JS
Joseph Schwartz
| $1.46 | $120 |
8,119%
upside
| Outperform |
18 Mar ‘22
3 years ago |
|
222
Neuropace
NPCE
$328M
|
DA
Danielle Antalffy
| $9.90 | $12 |
21%
upside
| Outperform |
11 Mar ‘22
3 years ago |
|
223
Procept Biorobotics
PRCT
$2.19B
|
DA
Danielle Antalffy
| $39.38 | $30 |
24%
downside
| Outperform |
9 Mar ‘22
3 years ago |
|
224
Disc Medicine
IRON
$2.17B
|
MG
Marc Goodman
| $62.47 | $2 |
97%
downside
| Market Perform |
3 Mar ‘22
3 years ago |
|
225
TruBridge
TBRG
$300M
|
SD
Stephanie Davis
| $19.96 | $38 |
90%
upside
| Outperform |
3 Mar ‘22
3 years ago |
|